Tucidinostat-based treatment for untreated DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years old or older.
- Must not have received any previous treatment for DLBCL, including chemotherapy, targeted therapy, or immunotherapy.
- The cancer must be a type of DLBCL that shows double expression of MYC and BCL2 (at least 40% MYC and 50% BCL2) OR has certain gene changes (like TP53, EZH2, or others).
- Must be planning to receive or already receiving a treatment plan that includes the drug tucidinostat.
- Must be willing and able to sign a consent form to participate.
- Cannot be enrolled in another clinical trial at the same time.
- Must have a doctor-estimated life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial compares two treatments for a certain type of aggressive lymphoma: the standard R-CHOP chemotherapy plus a study drug called tucidinostat (which may help fight cancer cells). The aim is to see if adding this drug helps patients with the double-expressor subtype do better.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.